Arthrosi Therapeutics

San Diego, CA Healthcare Acquired

Arthrosi Therapeutics is a clinical-stage biopharmaceutical company developing pozdeutinurad (AR882), a selective URAT1 inhibitor for the treatment of gout and tophaceous gout. The company was founded in 2018 by gout experts who previously led the clinical development of the first generation of urate-lowering therapies at Ardea Biosciences (acquired by AstraZeneca for $1.26B). Arthrosi has advanced its lead candidate through two fully enrolled Phase 3 clinical trials (REDUCE 1 and REDUCE 2) with data expected in 2026.

Acquired

Arthrosi Therapeutics has been acquired

Acquired by Swedish Orphan Biopharma (Sobi) February 2026 $950M upfront

This company is no longer available on our private secondary market.

Overview

Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Founded

2018

Employees

25–50

Total Funding

$1.21B

5 rounds

Latest Valuation

$0.95B

December 14, 2025

Funding

Total raised $1.21B across 5 rounds

Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Last updated 06-25-2026

Latest Round

Type

M&A exit (acquisition)

Date

December 14, 2025

Amount

$950M

Valuation

$0.95B

Lead Investors

Swedish Orphan Biovitrum - acquirer
DateRoundAmount RaisedValuationLead Investors
December 14, 2025 M&A exit (acquisition) $950M $0.95B Swedish Orphan Biovitrum - acquirer
June 23, 2025 Series E $153M $0.8B Prime Eight Capital
July 2023 Series D $75M Not disclosed in free sources

Funding by Round

Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Valuation Trajectory

Valuation indexed to 1.0× at the selected entry round. Valuation marks are estimates and may contain errors. Hover each dot to compare.

If you invested at:
1x Arthrosi Therapeutics

Entry · Series E

$0.8B

Jun 2025

Arthrosi Therapeutics today

$0.9B

Dec 2025 · latest mark

Arthrosi Therapeutics multiple

1.2x

valuation uplift since first round

Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.

Leadership

  • Litain Yeh

    CEO and Co-Founder

    LinkedIn
  • Shunqi Yan

    Co-Founder

  • Robert Thomas Keenan

    Chief Medical Officer

Access live market data

Sign Up

Data collected with AI, which can make mistakes. Please double-check this information.